Skip to main content
Top
Published in: Journal of General Internal Medicine 10/2020

01-10-2020 | SARS-CoV-2 | Perspective

Masks Do More Than Protect Others During COVID-19: Reducing the Inoculum of SARS-CoV-2 to Protect the Wearer

Authors: Monica Gandhi, MD, MPH, Chris Beyrer, MD, MPH, Eric Goosby, MD

Published in: Journal of General Internal Medicine | Issue 10/2020

Login to get access

Abstract

Although the benefit of population-level public facial masking to protect others during the COVID-19 pandemic has received a great deal of attention, we discuss for one of the first times the hypothesis that universal masking reduces the “inoculum” or dose of the virus for the mask-wearer, leading to more mild and asymptomatic infection manifestations. Masks, depending on type, filter out the majority of viral particles, but not all. We first discuss the near-century-old literature around the viral inoculum and severity of disease (conceptualized as the LD50 or lethal dose of the virus). We include examples of rising rates of asymptomatic infection with population-level masking, including in closed settings (e.g., cruise ships) with and without universal masking. Asymptomatic infections may be harmful for spread but could actually be beneficial if they lead to higher rates of exposure. Exposing society to SARS-CoV-2 without the unacceptable consequences of severe illness with public masking could lead to greater community-level immunity and slower spread as we await a vaccine. This theory of viral inoculum and mild or asymptomatic disease with SARS-CoV-2 in light of population-level masking has received little attention so this is one of the first perspectives to discuss the evidence supporting this theory.
Literature
4.
go back to reference Gandhi M, Yokoe DS, Havlir DV. Asymptomatic Transmission, the Achilles’ Heel of Current Strategies to Control Covid-19. N Engl J Med 2020; 382:2158-2160CrossRef Gandhi M, Yokoe DS, Havlir DV. Asymptomatic Transmission, the Achilles’ Heel of Current Strategies to Control Covid-19. N Engl J Med 2020; 382:2158-2160CrossRef
5.
go back to reference He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med 2020; 26(5): 672-5.CrossRef He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med 2020; 26(5): 672-5.CrossRef
7.
go back to reference Lyu W, Wehby GL. Community Use Of Face Masks And COVID-19: Evidence From A Natural Experiment Of State Mandates In The US. Health Aff (Millwood) 2020: 101377hlthaff202000818. Accessed June 22, 2020 Lyu W, Wehby GL. Community Use Of Face Masks And COVID-19: Evidence From A Natural Experiment Of State Mandates In The US. Health Aff (Millwood) 2020: 101377hlthaff202000818. Accessed June 22, 2020
10.
go back to reference Gandhi M, Havlir D. The Time for Universal Masking of the Public for Coronavirus Disease 2019 Is Now. Open Forum Infect Dis 2020; 7(4): ofaa131.CrossRef Gandhi M, Havlir D. The Time for Universal Masking of the Public for Coronavirus Disease 2019 Is Now. Open Forum Infect Dis 2020; 7(4): ofaa131.CrossRef
11.
go back to reference Eikenberry SE, Mancuso M, Iboi E, et al. To mask or not to mask: Modeling the potential for face mask use by the general public to curtail the COVID-19 pandemic. Infect Dis Model 2020; 5: 293-308.PubMedPubMedCentral Eikenberry SE, Mancuso M, Iboi E, et al. To mask or not to mask: Modeling the potential for face mask use by the general public to curtail the COVID-19 pandemic. Infect Dis Model 2020; 5: 293-308.PubMedPubMedCentral
12.
go back to reference Handel A, Li Y, McKay B, Pawelek KA, Zarnitsyna V, Antia R. Exploring the impact of inoculum dose on host immunity and morbidity to inform model-based vaccine design. PLoS Comput Biol 2018; 14(10): e1006505.CrossRef Handel A, Li Y, McKay B, Pawelek KA, Zarnitsyna V, Antia R. Exploring the impact of inoculum dose on host immunity and morbidity to inform model-based vaccine design. PLoS Comput Biol 2018; 14(10): e1006505.CrossRef
13.
go back to reference Miller DS, Kok T, Li P. The virus inoculum volume influences outcome of influenza A infection in mice. Lab Anim 2013; 47(1): 74-7.CrossRef Miller DS, Kok T, Li P. The virus inoculum volume influences outcome of influenza A infection in mice. Lab Anim 2013; 47(1): 74-7.CrossRef
14.
go back to reference Raoult D, Zumla A, Locatelli F, Ippolito G, Kroemer G. Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses. Cell Stress 2020; 4(4): 66-75.CrossRef Raoult D, Zumla A, Locatelli F, Ippolito G, Kroemer G. Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses. Cell Stress 2020; 4(4): 66-75.CrossRef
15.
go back to reference Yang R, Gui X, Xiong Y. Comparison of Clinical Characteristics of Patients with Asymptomatic vs Symptomatic Coronavirus Disease 2019 in Wuhan, China, JAMA Netw Open 2020; 3(5): e2010182.CrossRef Yang R, Gui X, Xiong Y. Comparison of Clinical Characteristics of Patients with Asymptomatic vs Symptomatic Coronavirus Disease 2019 in Wuhan, China, JAMA Netw Open 2020; 3(5): e2010182.CrossRef
16.
go back to reference Chan JF, Zhang AJ, Yuan S, et al. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin Infect Dis 2020. Chan JF, Zhang AJ, Yuan S, et al. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin Infect Dis 2020.
17.
go back to reference McKenney DG, Kurath G, Wargo AR. Characterization of infectious dose and lethal dose of two strains of infectious hematopoietic necrosis virus (IHNV). Virus Res 2016; 214: 80-9.CrossRef McKenney DG, Kurath G, Wargo AR. Characterization of infectious dose and lethal dose of two strains of infectious hematopoietic necrosis virus (IHNV). Virus Res 2016; 214: 80-9.CrossRef
18.
go back to reference Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. The American Journal of Hygiene. 1938;27(3):493-7. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. The American Journal of Hygiene. 1938;27(3):493-7.
19.
go back to reference Casadevall A. The Pathogenic Potential of a Microbe. mSphere 2017; 2(1). Casadevall A. The Pathogenic Potential of a Microbe. mSphere 2017; 2(1).
20.
go back to reference Bouvier NM, Lowen AC. Animal Models for Influenza Virus Pathogenesis and Transmission. Viruses 2010; 2(8): 1530-63.CrossRef Bouvier NM, Lowen AC. Animal Models for Influenza Virus Pathogenesis and Transmission. Viruses 2010; 2(8): 1530-63.CrossRef
21.
go back to reference Tao X, Garron T, Agrawal AS, et al. Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease. J Virol 2016; 90(1): 57-67.CrossRef Tao X, Garron T, Agrawal AS, et al. Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease. J Virol 2016; 90(1): 57-67.CrossRef
22.
go back to reference Gralinski LE, Ferris MT, Aylor DL, Whitmore AC, Green R, Frieman MB, et al. Genome Wide Identification of SARS-CoV Susceptibility Loci Using the Collaborative Cross. PLoS Genet. 2015;11(10):e1005504. .CrossRef Gralinski LE, Ferris MT, Aylor DL, Whitmore AC, Green R, Frieman MB, et al. Genome Wide Identification of SARS-CoV Susceptibility Loci Using the Collaborative Cross. PLoS Genet. 2015;11(10):e1005504. .CrossRef
23.
go back to reference Roberts A, Deming D, Paddock CD, et al. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog 2007; 3(1): e5.CrossRef Roberts A, Deming D, Paddock CD, et al. A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog 2007; 3(1): e5.CrossRef
24.
go back to reference Subbarao K, McAuliffe J, Vogel L, et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 2004; 78(7): 3572-7.CrossRef Subbarao K, McAuliffe J, Vogel L, et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 2004; 78(7): 3572-7.CrossRef
25.
go back to reference Virlogeux V, Fang VJ, Wu JT, et al. Brief Report: Incubation Period Duration and Severity of Clinical Disease Following Severe Acute Respiratory Syndrome Coronavirus Infection. Epidemiology 2015; 26(5): 666-9.CrossRef Virlogeux V, Fang VJ, Wu JT, et al. Brief Report: Incubation Period Duration and Severity of Clinical Disease Following Severe Acute Respiratory Syndrome Coronavirus Infection. Epidemiology 2015; 26(5): 666-9.CrossRef
28.
go back to reference Smereka J, Ruetzler K, Szarpak L, Filipiak KJ, Jaguszewski M. Role of mask/respirator protection against SARS-CoV-2. Anesth Analg 2020. Accessed June 22, 2020 Smereka J, Ruetzler K, Szarpak L, Filipiak KJ, Jaguszewski M. Role of mask/respirator protection against SARS-CoV-2. Anesth Analg 2020. Accessed June 22, 2020
29.
go back to reference Engelking HM, Leong JC. The glycoprotein of infectious hematopoietic necrosis virus elicits neutralizing antibody and protective responses. Virus Res 1989; 13(3): 213-30.CrossRef Engelking HM, Leong JC. The glycoprotein of infectious hematopoietic necrosis virus elicits neutralizing antibody and protective responses. Virus Res 1989; 13(3): 213-30.CrossRef
30.
go back to reference S.E. LaPatra, J.L. Fryer, J.S. Rohovec. Virulence comparison of different electropherotypes of infectious hematopoietic necrosis virus. Dis. Aquat. Org., 16 (1993), pp. 115-1.CrossRef S.E. LaPatra, J.L. Fryer, J.S. Rohovec. Virulence comparison of different electropherotypes of infectious hematopoietic necrosis virus. Dis. Aquat. Org., 16 (1993), pp. 115-1.CrossRef
31.
go back to reference Kim R, Faisal M. Comparative susceptibility of representative Great Lakes fish species to the North American viral hemorrhagic septicemia virus Sublineage IVb. Dis Aquat Organ 2010; 91(1): 23-34.CrossRef Kim R, Faisal M. Comparative susceptibility of representative Great Lakes fish species to the North American viral hemorrhagic septicemia virus Sublineage IVb. Dis Aquat Organ 2010; 91(1): 23-34.CrossRef
32.
go back to reference Brown JD, Stallknecht DE, Berghaus RD, Swayne DE. Infectious and lethal doses of H5N1 highly pathogenic avian influenza virus for house sparrows (Passer domesticus) and rock pigeons (Columbia livia). J Vet Diagn Invest 2009; 21(4): 437-45.CrossRef Brown JD, Stallknecht DE, Berghaus RD, Swayne DE. Infectious and lethal doses of H5N1 highly pathogenic avian influenza virus for house sparrows (Passer domesticus) and rock pigeons (Columbia livia). J Vet Diagn Invest 2009; 21(4): 437-45.CrossRef
33.
go back to reference S.E. LaPatra, J.L. Fryer, J.S. Rohovec. Virulence comparison of different electropherotypes of infectious hematopoietic necrosis virus. Dis. Aquat. Org., 16 (1993), pp. 115-120.CrossRef S.E. LaPatra, J.L. Fryer, J.S. Rohovec. Virulence comparison of different electropherotypes of infectious hematopoietic necrosis virus. Dis. Aquat. Org., 16 (1993), pp. 115-120.CrossRef
34.
go back to reference Memoli MJ, Czajkowski L, Reed S, et al. Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study. Clin Infect Dis 2015; 60(5): 693-702.CrossRef Memoli MJ, Czajkowski L, Reed S, et al. Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study. Clin Infect Dis 2015; 60(5): 693-702.CrossRef
37.
go back to reference Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill 2020; 25(10). Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill 2020; 25(10).
39.
go back to reference Hains DS, Schwaderer AL, Carroll AE, et al. Asymptomatic Seroconversion of Immunoglobulins to SARS-CoV-2 in a Pediatric Dialysis Unit. JAMA 2020;323(23):2424-2425CrossRef Hains DS, Schwaderer AL, Carroll AE, et al. Asymptomatic Seroconversion of Immunoglobulins to SARS-CoV-2 in a Pediatric Dialysis Unit. JAMA 2020;323(23):2424-2425CrossRef
Metadata
Title
Masks Do More Than Protect Others During COVID-19: Reducing the Inoculum of SARS-CoV-2 to Protect the Wearer
Authors
Monica Gandhi, MD, MPH
Chris Beyrer, MD, MPH
Eric Goosby, MD
Publication date
01-10-2020
Publisher
Springer International Publishing
Published in
Journal of General Internal Medicine / Issue 10/2020
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-020-06067-8

Other articles of this Issue 10/2020

Journal of General Internal Medicine 10/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.